Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.21
-2.5%
$4.52
$3.42
$7.57
$292.82M1.941.56 million shs1.68 million shs
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$8.34
+0.5%
$8.02
$5.11
$10.67
$1.13B1.161.32 million shs857,235 shs
89bio, Inc. stock logo
ETNB
89bio
$9.62
+6.5%
$7.27
$4.16
$11.84
$1.40B1.231.41 million shs2.84 million shs
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$10.37
-9.1%
$9.05
$6.11
$19.00
$971.99M1.996,046 shs82,476 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+6.37%+3.49%+20.27%-7.77%-27.84%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+2.85%+6.14%+6.93%+5.46%+43.60%
89bio, Inc. stock logo
ETNB
89bio
+17.27%+15.77%+49.01%-20.09%+1.01%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
+2.61%-0.87%+28.38%-6.10%-21.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4593 of 5 stars
0.02.00.00.02.40.80.6
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
2.4527 of 5 stars
3.51.00.00.02.50.81.9
89bio, Inc. stock logo
ETNB
89bio
2.8936 of 5 stars
4.51.00.00.03.80.80.6
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.2792 of 5 stars
0.02.00.00.01.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5037.86% Upside
89bio, Inc. stock logo
ETNB
89bio
3.00
Buy$26.43174.87% Upside
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ACB, ETNB, AUPH, and GYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2025
89bio, Inc. stock logo
ETNB
89bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/30/2025
89bio, Inc. stock logo
ETNB
89bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/24/2025
89bio, Inc. stock logo
ETNB
89bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/8/2025
89bio, Inc. stock logo
ETNB
89bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
3/22/2025
89bio, Inc. stock logo
ETNB
89bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
3/14/2025
89bio, Inc. stock logo
ETNB
89bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$11.00
3/13/2025
89bio, Inc. stock logo
ETNB
89bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
3/11/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/7/2025
89bio, Inc. stock logo
ETNB
89bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
2/28/2025
89bio, Inc. stock logo
ETNB
89bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $21.00
(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.91$0.20 per share26.35$8.18 per share0.64
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.56N/AN/A$2.63 per share3.17
89bio, Inc. stock logo
ETNB
89bio
N/AN/AN/AN/A$5.75 per shareN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$100.64M9.66$0.21 per share50.49$0.18 per share57.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05104.2011.84N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M$0.28N/A14.90N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)
89bio, Inc. stock logo
ETNB
89bio
-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M$0.02518.35N/A-84.57%-118.43%-71.97%N/A

Latest ACB, ETNB, AUPH, and GYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/9/2025Q1 2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.03$0.03N/AN/A$28.40 million$22.06 million
5/1/2025Q1 2025
89bio, Inc. stock logo
ETNB
89bio
-$0.50-$0.49+$0.01-$0.49N/AN/A
3/17/2025Q4 2024
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.04$0.01-$0.03$0.02$23.50 million$27.87 million
3/6/2025Q4 2024
89bio, Inc. stock logo
ETNB
89bio
-$0.60-$1.02-$0.42-$1.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
89bio, Inc. stock logo
ETNB
89bio
N/AN/AN/AN/AN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.17
5.60
5.11
89bio, Inc. stock logo
ETNB
89bio
0.09
11.66
11.66
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
3.72
3.29

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
89bio, Inc. stock logo
ETNB
89bio
N/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
4.30%
89bio, Inc. stock logo
ETNB
89bio
2.60%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
19.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million137.02 millionOptionable
89bio, Inc. stock logo
ETNB
89bio
40145.98 million103.15 millionOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4093.76 million75.27 millionNo Data

Recent News About These Companies

Gyre Therapeutics, Inc. Common Stock
Gyre Therapeutics announces NMPA approval for trial on pirfenidone
Gyre Therapeutics offers weak 2025 revenue guidance
Gyre Therapeutics (GYRE) Receives a Buy from Noble Financial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.21 -0.13 (-2.45%)
Closing price 03:59 PM Eastern
Extended Trading
$5.21 +0.00 (+0.02%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.34 +0.04 (+0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$8.26 -0.09 (-1.03%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

89bio stock logo

89bio NASDAQ:ETNB

$9.62 +0.59 (+6.48%)
Closing price 03:59 PM Eastern
Extended Trading
$9.60 -0.02 (-0.21%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$10.37 -1.03 (-9.06%)
Closing price 03:59 PM Eastern
Extended Trading
$10.68 +0.32 (+3.06%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.